Previous close | 0.1140 |
Open | 0.1330 |
Bid | 0.1150 x 0 |
Ask | 0.1300 x 0 |
Day's range | 0.1330 - 0.1330 |
52-week range | 0.1070 - 0.1860 |
Volume | |
Avg. volume | 62 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
FREMONT, Calif., April 12, 2023--Nova Eye Medical Limited (ASX: EYE) (Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces that it has been granted U.S. Food and Drug Administration (FDA) 510(k) clearance for its new canaloplasty device, iTrack™ Advance.